(Total Views: 365)
Posted On: 01/27/2022 2:49:16 PM
Post# of 145246
Take a look at 2.06, Material Impairments. I am thinking that leronlimab is a material asset of CYDY and thus its failure in a trial would be a material impairment of that asset.
Thoughts?
Thoughts?
(0)
(0)